文献速递临床试验与 GCP流行病学与生物统计

长效玻璃体内氟轻松植入物与全身抗炎治疗对中间型、后型或全葡萄膜炎患者7年视力关联的比较

Association Between Long-Lasting Intravitreous Fluocinolone Acetonide Implant vs Systemic Anti-inflammatory Therapy and Visual Acuity at 7 Years Among Patients With Intermediate, Posterior, or Panuveitis.
PubMed 文献 · JAMA · 2017-01-01

该研究为MUST随机临床试验的非预设7年观察性随访,比较玻璃体内氟轻松植入物与全身糖皮质激素联合免疫抑制治疗对葡萄膜炎视力的长期影响。结果显示,全身治疗组7年视力优于植入物组,平均视力变化差异为7.2个字母(95%CI 2.1-12),支持全身治疗。研究解读受失访限制。

要点

  • 在严重中间型、后型或全葡萄膜炎患者中,7年随访时全身治疗组视力优于玻璃体内氟轻松植入物组。
  • 平均视力变化从基线至7年,植入物组与全身治疗组差异为7.2个字母(95%CI 2.1-12),利于全身治疗。
  • 研究解读受失访限制。

核心结论

  • 在严重中间型、后型或全葡萄膜炎患者的7年扩展随访中,随机接受全身治疗者的视力优于随机接受玻璃体内氟轻松植入物者。

研究设计与样本

  • MUST随机临床试验的非预设7年观察性随访,比较玻璃体内氟轻松植入物与全身糖皮质激素联合免疫抑制治疗。
  • 随访在美国21家、英国1家和澳大利亚1家三级葡萄膜炎专科诊所进行。
  • 255例13岁及以上、活动期在60天内的中间型、后型或全葡萄膜炎患者于2005年12月6日至2008年12月9日入组,其中215例同意随访至少7年(末次访视2016年2月10日)。
  • 共获得161只植入物组患眼(90例患者的70%)和167只全身治疗组患眼(90例患者的71%)的7年数据;77%为女性,入组中位年龄48岁(四分位距36-56)。

主要发现

  • 平均视力从基线(植入物组61.7,全身治疗组65.0)至7年(植入物组55.8,全身治疗组66.2),全身治疗组优于植入物组7.2个字母(95%CI 2.1-12)。
  • 预设前瞻性收集的全身不良结局7年累积发生率在植入物组与全身治疗组分别为:高脂血症6.1% vs 11.2%,高血压9.8% vs 18.4%,骨质减少41.5% vs 43.1%,骨折11.3% vs 18.6%,住院47.6% vs 42.3%,抗生素治疗感染57.4% vs 72.3%;除上述外均低于10%。

局限性

  • 研究解读受失访限制。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: A randomized clinical trial comparing fluocinolone acetonide implant vs systemic corticosteroids and immunosuppression for treatment of severe noninfectious intermediate, posterior, and panuveitides did not result in a significant difference in visual acuity at 2 and 4.5 years; longer-term outcomes are not known. OBJECTIVE: To compare the association between intravitreous fluocinolone acetonide implant vs systemic therapy and long-term visual and other outcomes in patients with uveitis. DESIGN, SETTING, AND PARTICIPANTS: Nonprespecified 7-year observational follow-up of the Multicenter Uveitis Steroid Treatment (MUST) randomized clinical trial comparing the alternative treatments. Follow-up was conducted in tertiary uveitis subspecialty practices in the United States (21), the United Kingdom (1), and Australia (1). Of 255 patients 13 years or older with intermediate, posterior, or panuveitis (active within ≤60 days) enrolled in the MUST trial between December 6, 2005, and December 9, 2008, 215 consented to ongoing follow-up through at least 7 years postrandomization (last visit, February 10, 2016). INTERVENTIONS: Participants had been randomized to receive a surgically placed intravitreous fluocinolone acetonide implant or systemic corticosteroids supplemented by immunosuppression. When both eyes required treatment, both eyes were treated. MAIN OUTCOMES AND MEASURES: Primary outcome was change from baseline in best-corrected visual acuity in uveitic eyes (5 letters = 1 visual acuity chart line; potential range of change in letters read, -121 to +101; minimal clinically important difference, 7 letters), analyzed by treatment assignment accounting for nonindependence of eyes when patients had 2 uveitic eyes. Secondary outcomes included potential systemic toxicities of corticosteroid and immunosuppressive therapy and death. RESULTS: Seven-year data were obtained for 161 uveitic eyes (70% of 90 patients assigned to implant) and 167 uveitic eyes (71% of 90 patients assigned to systemic therapy) (77% female; median age at enrollment, 48 [interquartile range, 36-56] years). Change in mean visual acuity from baseline (implant, 61.7; systemic therapy, 65.0) through 7 years (implant, 55.8; systemic therapy, 66.2) favored systemic therapy by 7.2 (95% CI, 2.1-12) letters. Among protocol-specified, prospectively collected systemic adverse outcomes, the cumulative 7-year incidence in the implant and systemic therapy groups, respectively, was less than 10%, with the exceptions of hyperlipidemia (6.1% vs 11.2%), hypertension (9.8% vs 18.4%), osteopenia (41.5% vs 43.1%), fractures (11.3% vs 18.6%), hospitalization (47.6% vs 42.3%), and antibiotic-treated infection (57.4% vs 72.3%). CONCLUSIONS AND RELEVANCE: In 7-year extended follow-up of a randomized trial of patients with severe intermediate, posterior, or panuveitis, those randomized to receive systemic therapy had better visual acuity than those randomized to receive intravitreous fluocinolone acetonide implants. Study interpretation is limited by loss to follow-up. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00132691.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Kempen JH, Altaweel MM, Holbrook JT, et al. Association Between Long-Lasting Intravitreous Fluocinolone Acetonide Implant vs Systemic Anti-inflammatory Therapy and Visual Acuity at 7 Years Among Patients With Intermediate, Posterior, or Panuveitis. JAMA. 2017. PMID: 28477440. doi:10.1001/jama.2017.5103

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。